Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor α receptor IgG1-Fc fusion complex therapy

被引:98
作者
Smith, KJ
Skelton, HG
机构
[1] Natl Naval Med Ctr, Dept Dermatol, Bethesda, MD USA
[2] Lab Corp Amer, Herndon, VA USA
关键词
D O I
10.1067/mjd.2001.117725
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Tumor necrosis factor a (TNF-alpha) is now believed to be a major contributor to the pathogenesis of the synovitis and joint destruction in rheumatoid arthritis. Etanercept is a recombinant human TNF-alpha receptor Fc fusion protein consisting of a dimer of the extracellular portion of two p75 TNF-alpha receptors fused to the Fc portion of human IgG1. Etanercept produces significant dose-dependent improvements in disease activity. We describe 7 patients who experienced 1 or move squamous cell carcinomas that showed rapid growth and arose over a 2- to 4-month period of etanercept therapy Soluble TNF-alpha receptor therapy through inhibition of a T(H)1 cytokine pattern and inhibition of the direct and indirect cytotoxic effects of TNF-alpha may initially decrease mechanisms for controlling subclinical tumors and may contribute to the histologic features seen within these tumors. However, prolonged TNF-alpha inhibition may have some antitumor effects.
引用
收藏
页码:953 / 956
页数:4
相关论文
共 20 条
[1]  
ABBAS AK, 1997, CELLULAR MOL IMMUNOL, P250
[2]  
Becher B, 1999, J IMMUNOL, V162, P684
[3]   Anti-TNFα therapy is useful in rheumatoid arthritis and Crohn's disease:: Analysis of the mechanism of action predicts utility in other diseases [J].
Feldman, M ;
Taylor, P ;
Paleolog, E ;
Brennan, FM ;
Maini, RN .
TRANSPLANTATION PROCEEDINGS, 1998, 30 (08) :4126-4127
[4]  
Feldmann M, 1998, SPRINGER SEMIN IMMUN, V20, P211, DOI 10.1007/BF00832008
[5]   Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis [J].
Goldenberg, MM .
CLINICAL THERAPEUTICS, 1999, 21 (01) :75-87
[6]   Anti-tumor necrosis factor-α monoclonal antibody therapy for rheumatoid arthritis [J].
Kavanaugh, AF .
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 1998, 24 (03) :593-+
[7]   Signal transduction through NF-κB [J].
May, MJ ;
Ghosh, S .
IMMUNOLOGY TODAY, 1998, 19 (02) :80-88
[8]   Tissue-specific migration of lymphocytes: A key role for Th1 and Th2 cells? [J].
Meeusen, ENT ;
Premier, RR ;
Brandon, MR .
IMMUNOLOGY TODAY, 1996, 17 (09) :421-424
[9]   Bypassing the antigen to control rheumatoid arthritis [J].
Miossec, P ;
Chomarat, P ;
Dechanet, J .
IMMUNOLOGY TODAY, 1996, 17 (04) :170-173
[10]   Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis [J].
Moore, RJ ;
Owens, DM ;
Stamp, G ;
Arnott, C ;
Burke, F ;
East, N ;
Holdsworth, H ;
Turner, L ;
Rollins, B ;
Pasparakis, M ;
Kollias, G ;
Balkwill, F .
NATURE MEDICINE, 1999, 5 (07) :828-831